Latest Press Releases
Canadian patent application relating to uTRACE[®] is ready for allowance in Canada
First day of trading in Curasight’s shares and warrants at Spotlight Stock Market
Prolongation and expansion of agreement with TRT Innovations ApS
Company
Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer.
Technology
Curasight builds its novel uPAR-PET imaging approach on a deep understanding of the uPAR system and it’s role in cancer, together with extensive experience with translational molecular imaging, which has been obtained through more than a decade of research at Rigshospitalet and University of Copenhagen
Pipeline
Curasight is focused on addressing the need for improved diagnosis and treatment of brain and prostate cancer. Curasight build on its foundation of pioneering research and development within uPAR-PET Imaging. Our clinical development efforts include a program to develop a first-in-class uPAR-PET imaging ligand which is currently in phase II clinical testing
What is Molecular Nuclear Imaging?
Uses trace amount of radioactive substances called radiopharmaceuticals to reveal specific biochemical processes.